The FDA is warning patients and health care providers that certain Medtronic MiniMed™ insulin pumps have potential cybersecurity risks. Patients with diabetes using these models should switch their insulin pump to models that are better equipped to protect against these potential risks
Diabetes News
Category: Devices
Medtronic gains approval of first artificial pancreas
Medtronic’s system is the first in the United States that can automatically stop insulin delivery when sensor glucose values reach a preset level and when the patient doesn’t respond to the Threshold Suspend alarm … As a condition of approval, in addition to the post-approval study, Medtronic will engage in direct patient follow up and will make certain manufacturing accommodations (Medtronic)
Accuracy glucose meters & arterial blood gas analyzers in critically ill
Our literature review showed that the accuracy of blood glucose measurements by arterial blood gas analyzers was significantly higher than that of measurements by glucose meters using capillary blood and tended to be higher than that of measurements by glucose meters using arterial blood (Critical Care)
Structured educational insulin pump programme: children/young people
The insulin pump therapy programme was appreciated by the majority of families, and provided children and their parents with support for easier transition from insulin injections to pumps. As the numbers of young people using pump therapy increase, the results of this study can inform the development of similar services, by considering this programme as a model for establishing such a service in other specialised diabetes centres (European Diabetes Nursing)
Continuous glucose monitors: current status and future developments
In a widening set of circumstances, use of CGM has been shown to promote safer and more effective glycemic control than self-monitoring of blood glucose. Imperfections remain in certain scenarios such as hypoglycemia and in certain populations such as young children (Current Opinion in Endocrinology, Diabetes & Obesity)
Insulin pump therapy in T2D after failure of multiple daily injections
We found that CSII in patients with DM2 who have failed MDI improves glucose control despite a decrease in overall insulin requirements. This includes patients with severe insulin resistance using U-500 insulin. Use of frequent bolus adjustment incorporating carbohydrate counting and current glucose level does not appear to be required for this benefit (Endocrine Practice)